Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GRM5 | P41594 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GCK | P35557 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29236353 | 1.00 | MAPT (0.57) | MAPTGRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL29236356 | 0.89 | MAPT (0.59) | MAPTGRM5NPC1RAB9AKDM4E | |
| SCHEMBL31027176 | 0.89 | MAPT (0.59) | MAPTGRM5NPC1RAB9AKDM4E | |
| SCHEMBL30300345 | 0.88 | GRM5 (0.57) | MAPTGRM5CYP3A4NPC1RAB9A | |
| SCHEMBL31318875 | 0.87 | MAPT (0.54) | MAPTGRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL30300303 | 0.85 | MAPT (0.54) | MAPTGRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL31318883 | 0.84 | MAPT (0.50) | MAPTNPC1RAB9AKDM4EHTT | |
| SCHEMBL31318881 | 0.83 | MAPT (0.51) | MAPTNPC1RAB9AKDM4EHTT | |
| SCHEMBL31318892 | 0.83 | MAPT (0.57) | MAPTGRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL1794081 | 0.82 | NPC1 (0.58) | MAPTGRM5NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2024-11-28 | — | — | US | disclosed |
| CN-118234718-A | Phenyl core compounds as MGLU5 negative allosteric modulators and methods of making and using the same | 范德比尔特大学 | 2024-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | MAPT 266/4885GRM5 1/4885CYP3A4 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.